Market Place
Sourcing Support
Theriva Publishes VCN-01 Phase 1 Results for Head & Neck Cancer
11 Jun 2026 //
GLOBENEWSWIRE
Ampligen Plus Imfinzi Shows Promise Result in Pancreatic Cancer
08 Jun 2026 //
GLOBENEWSWIRE
Astrazeneca`s Triplet Combo Succeeds In Liver Cancer Subgroup
01 Jun 2026 //
FIERCE PHARMA
AIM Completes DURIPANC Phase 2 Enrollment Ahead of Schedule
01 Jun 2026 //
GLOBENEWSWIRE
Combo Immunotherapy Cuts Kidney Cancer Recurrence Post-Surgery
30 May 2026 //
ICR
AstraZeneca Gains 2nd Bladder Cancer Nod for Imfinzi
28 May 2026 //
FIERCE PHARMA
AstraZeneca to Share Phase 3 Cancer Data at ASCO 2026
22 May 2026 //
PRESS RELEASE
Durvalumab Combo May Help High-Risk Bladder Cancer Avoid Surgery
20 May 2026 //
FIRSTWORD PHARMA
Astrazeneca Follows Merck With Phase 3 Win In Bladder Cancer
15 May 2026 //
ENDPOINTS
VOLGA Trial: Imfinzi Plus EV Boosts Survival in Bladder Cancer
14 May 2026 //
BUSINESSWIRE
Innate Pharma To Unveil IPH5201 Phase 2 Interim Results At AACR
17 Apr 2026 //
FIRSTWORD PHARMA
IMFINZI + IMJUDO Improves PFS in Early Liver Cancer
02 Apr 2026 //
BUSINESSWIRE
AstraZeneca Pharma India receives CDSCO approval for Durvalumab
17 Mar 2026 //
EXPRESSPHARMA
AIM ImmunoTech Signs Ampligen Phase 3 Trial Deal
02 Mar 2026 //
GLOBENEWSWIRE
AstraZeneca Gets CDSCO Nod for Imfinzi in New Indication
10 Feb 2026 //
ECONOMICTIMES
AstraZeneca Wins CDSCO Nod for Durvalumab in Gastric Cancer
06 Feb 2026 //
ECONOMICTIMES
AIM Reports Positive Interim Ph2 Data of Ampligen Combo in Cancer
05 Feb 2026 //
GLOBENEWSWIRE
AIM Immunotech Announces Release Of The Next CEO Corner Segment
10 Dec 2025 //
GLOBENEWSWIRE
AIM Immunotech Joins Virtual Investor Closing Bell Series
01 Dec 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Reports Q3 2025 Financials on Pancreatic Cancer
18 Nov 2025 //
GLOBENEWSWIRE
Imfinzi Reduces Death Risk By 32% In High-Risk Bladder Cancer
22 Oct 2025 //
INDPHARMAPOST
AZ Faces FDA Challenge As Imfinzi-Lynparza Miss Survival Goal
19 Oct 2025 //
FIERCE PHARMA
Imfinzi Cuts Death Risk 22% in Early Gastric Cancer Ph3
17 Oct 2025 //
BUSINESSWIRE
Imfinzi Cuts Recurrence Risk 32% in NMIBC Ph3 POTOMAC
17 Oct 2025 //
BUSINESSWIRE
Akeso Completes Ph3 Enrollment for Ivonescimab in Biliary Cancer
02 Sep 2025 //
PR NEWSWIRE
Imfinzi Gets Priority Review, Breakthrough Therapy Status in US
31 Jul 2025 //
INDPHARMAPOST
Imfinzi Gets US Priority Review for Early-Stage Gastric Cancers
28 Jul 2025 //
BUSINESSWIRE
AIM Reports Positive Ph2 Data on Ampligen + Imfinzi in Cancer
28 Jul 2025 //
GLOBENEWSWIRE
AstraZeneca Gains CDSCO Approval for Treatment of Bladder Cancer
15 Jul 2025 //
EXPRESSPHARMA
Imfinzi Approved in EU as First Perioperative Immunotherapy
04 Jul 2025 //
PRESS RELEASE
AstraZeneca Pharma India Approved for Endometrial Cancer
02 Jul 2025 //
EXPRESSPHARMA
Imfinzi Regimen Cuts Progression Risk 29% In Gastric Cancer
01 Jun 2025 //
BUSINESSWIRE
AZ`s Imfinzi checks off a win in high-risk bladder cancer study
10 May 2025 //
FIERCE PHARMA
Imfinzi® Regimen Shows Significant Improvement in Bladder Cancer
09 May 2025 //
BUSINESSWIRE
AZ`s Imfinzi wins perioperative FDA nod in bladder cancer
01 Apr 2025 //
FIERCE PHARMA
Imfinzi Shows EFS Benefit In Early Gastric, GEJ Cancers
07 Mar 2025 //
BUSINESSWIRE
AstraZeneca gets CDSCO approval to import, sell cancer medicine
04 Mar 2025 //
ECONOMICTIMES
AIM doses first subject in Phase 2 study of Ampligen and Imfinzi
25 Feb 2025 //
GLOBENEWSWIRE
IMFINZI Perioperative Regimen Boosts Survival In Bladder Cancer
14 Feb 2025 //
BUSINESSWIRE
AIM ImmunoTech Releases Virtual Investor “What This Means” Segment
11 Feb 2025 //
GLOBENEWSWIRE
Erasmus Safety Committee Approves Ph 2 Study for Pancreatic Cancer
05 Feb 2025 //
GLOBENEWSWIRE
FDA approves Imfinzi for limited-stage small cell lung cancer
05 Dec 2024 //
REUTERS
AstraZeneca`s Biologic Imfinzi Receives Suppl Approval in US
04 Dec 2024 //
FDA
Akeso Enrolls 1st Patient in Ivonescimab Biliary Tract Cancer Trial
31 Oct 2024 //
PR NEWSWIRE
Govt asks manufacturers to cut price of 3 anti-cancer drugs
29 Oct 2024 //
ECONOMICTIMES
AstraZeneca Pharma India to launch Tremelimumab
23 Sep 2024 //
INDIANPHARMAPOST
AIM ImmunoTech Reports Positive Data In Pancreatic Cancer Study
19 Sep 2024 //
GLOBENEWSWIRE
AstraZeneca`s Imfinzi extends life in bladder cancer type
17 Sep 2024 //
FIERCE PHARMA
Imfinzi Plus Imjudo Shows 5-Year Survival In Liver Cancer
16 Sep 2024 //
BUSINESSWIRE
IMFINZI Reduces Recurrence Risk In Bladder Cancer In NIAGARA Trial
15 Sep 2024 //
BUSINESSWIRE
Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer
12 Sep 2024 //
PR NEWSWIRE
AstraZeneca Advances Cancer Care Standards at WCLC and ESMO 2024
03 Sep 2024 //
BUSINESSWIRE
Imfinzi Approved In U.S. For Resectable Non-Small Cell Lung Cancer
16 Aug 2024 //
BUSINESSWIRE
AstraZeneca`s Imfinzi gets FDA priority review for type of lung cancer
15 Aug 2024 //
REUTERS
Argenx`s Vyvgart Competes Well With AstraZeneca In Myasthenia Gravis
25 Jul 2024 //
FIERCE PHARMA
AstraZeneca`s Biologic Imfinzi (Durvalumab) Receives Suppl Approvals in US
24 Jul 2024 //
FDA
FDA Flags Potential ‘Overtreatment’ for NSCLC With AstraZeneca’s Imfinzi
24 Jul 2024 //
BIOSPACE
AZ`s Imfinzi fails in late-stage trial to treat certain lung cancers
26 Jun 2024 //
REUTERS
IMFINZI shows results in Phase III trial for muscle-invasive bladder cancer.
25 Jun 2024 //
BUSINESSWIRE
AZ Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
17 Jun 2024 //
REUTERS
